Clinical significance of antibodies to Ro52/TRIM21 in systemic sclerosis

Arthritis Research and Therapy

Volumn 14, Issue 2, 2012, Pages

  Hudson, Marie ^a,b   Pope, Janet ^c   Mahler, Michael ^d   Tatibouet, Solène ^b   Steele, Russell ^b   Baron, Murray ^a,b   Fritzler, Marvin J ^e  

^a MCGILL UNIVERSITY   (Canada)

^b MCGILL UNIVERSITY   (Canada)

^c WESTERN UNIVERSITY   (Canada)

^d INOVA DIAGNOSTICS INC   (United States)

^e UNIVERSITY OF CALGARY   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

AUTOANTIBODY; CENTROMERE ANTIBODY; CENTROMERE PROTEIN A; DNA DIRECTED RNA POLYMERASE III; DNA TOPOISOMERASE INHIBITOR; RO ANTIBODY; RO52 ANTIBODY; SM ANTIBODY; TRIPARTITE MOTIF PROTEIN 21 ANTIBODY; UNCLASSIFIED DRUG; BIOLOGICAL MARKER; RIBONUCLEOPROTEIN; SS A ANTIGEN; SS-A ANTIGEN;

ADULT; ANTIBODY DETECTION; ARTICLE; CHROMATIN; CLINICAL FEATURE; CROSS-SECTIONAL STUDY; DERMATOMYOSITIS; DISEASE ASSOCIATION; DISEASE DURATION; DISEASE SEVERITY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; GASTROINTESTINAL SYMPTOM; HUMAN; IMMUNOASSAY; IMMUNOFLUORESCENCE; INTERSTITIAL LUNG DISEASE; LUNG ARTERY PRESSURE; MAJOR CLINICAL STUDY; MALE; MIXED CONNECTIVE TISSUE DISEASE; MYOSITIS; POLYMYOSITIS; PROGNOSIS; PULMONARY HYPERTENSION; RHEUMATOID ARTHRITIS; SJOEGREN SYNDROME; SYSTEMIC LUPUS ERYTHEMATOSUS; SYSTEMIC SCLEROSIS; THROMBOSIS; AGED; BIOSYNTHESIS; BLOOD; COHORT ANALYSIS; IMMUNOLOGY; METABOLISM; MIDDLE AGED; MULTICENTER STUDY;

ADULT; AGED; AUTOANTIBODIES; BIOLOGICAL MARKERS; COHORT STUDIES; CROSS-SECTIONAL STUDIES; FEMALE; HUMANS; MALE; MIDDLE AGED; RIBONUCLEOPROTEINS; SCLERODERMA, SYSTEMIC;

EID: 84858837450     PISSN: 14786354     EISSN: 14786362     Source Type: Journal    
DOI: 10.1186/ar3763     Document Type: Article

References (47)

1. Steen VD. Autoantibodies in systemic sclerosis. Semin Arthritis Rheum 2005, 35:35-42. 10.1016/j.semarthrit.2005.03.005, 16084222.
2. Mahler M, Raijmakers R. Novel aspects of autoantibodies to the PM/Scl complex: clinical, genetic and diagnostic insights. Autoimmun Rev 2007, 6:432-437. 10.1016/j.autrev.2007.01.013, 17643929.
3. Reveille JD, Solomon DH. Evidence-based guidelines for the use of immunologic tests: anticentromere, Scl-70, and nucleolar antibodies. Arthritis Rheum 2003, 49:399-412. 10.1002/art.11113, 12794797.
4. Walker JG, Fritzler MJ. Update on autoantibodies in systemic sclerosis. Curr Opin Rheumatol 2007, 19:580-591. 10.1097/BOR.0b013e3282e7d8f9, 17917539.
5. Arnett FC, Gourh P, Shete S, Ahn CW, Honey RE, Agarwal SK, Tan FK, McNearney T, Fischbach M, Fritzler MJ, Mayes MD, Reveille JD. Major histocompatibility complex (MHC) class II alleles, haplotypes and epitopes which confer susceptibility or protection in systemic sclerosis: analyses in 1300 Caucasian, African-American and Hispanic cases and 1000 controls. Ann Rheum Dis 2010, 69:822-827. 10.1136/ard.2009.111906, 2916702,2916702, 19596691.
6. Robitaille G, Christin MS, Clement I, Senecal JL, Raymond Y. Nuclear autoantigen CENP-B transactivation of the epidermal growth factor receptor via chemokine receptor 3 in vascular smooth muscle cells. Arthritis Rheum 2009, 60:2805-2816. 10.1002/art.24765, 19714638.
7. Henault J, Robitaille G, Senecal JL, Raymond Y. DNA topoisomerase I binding to fibroblasts induces monocyte adhesion and activation in the presence of anti-topoisomerase I autoantibodies from systemic sclerosis patients. Arthritis Rheum 2006, 54:963-973. 10.1002/art.21646, 16508979.
8. Henault J, Tremblay M, Clement I, Raymond Y, Senecal JL. Direct binding of anti-DNA topoisomerase I autoantibodies to the cell surface of fibroblasts in patients with systemic sclerosis. Arthritis Rheum 2004, 50:3265-3274. 10.1002/art.20515, 15476238.
9. Baroni SS, Santillo M, Bevilacqua F, Luchetti M, Spadoni T, Mancini M, Fraticelli P, Sambo P, Funaro A, Kazlauskas A, Avvedimento EV, Gabrielli A. Stimulatory autoantibodies to the PDGF receptor in systemic sclerosis. N Engl J Med 2006, 354:2667-2676. 10.1056/NEJMoa052955, 16790699.
10. Racanelli V, Prete M, Musaraj G, Dammacco F, Perosa F. Autoantibodies to intracellular antigens: generation and pathogenetic role. Autoimmun Rev 2011, 10:503-508. 10.1016/j.autrev.2011.03.001, 21397735.
11. Hervier B, Rimbert M, Colonna F, Hamidou MA, Audrain M. Clinical significance of anti-Ro/SSA-52 kDa antibodies: a retrospective monocentric study. Rheumatology (Oxford) 2009, 48:964-967.
12. Thompson AE, Pope JE. Increased prevalence of scleroderma in southwestern Ontario: a cluster analysis. J Rheumatol 2002, 29:1867-1873.
13. Bernatsky S, Joseph L, Pineau CA, Belisle P, Hudson M, Clarke AE. Scleroderma prevalence: demographic variations in a population-based sample. Arthritis Rheum 2009, 61:400-404. 10.1002/art.24339, 19248123.
14. Chifflot H, Fautrel B, Sordet C, Chatelus E, Sibilia J. Incidence and prevalence of systemic sclerosis: a systematic literature review. Semin Arthritis Rheum 2008, 37:223-235. 10.1016/j.semarthrit.2007.05.003, 17692364.
15. Lonzetti LS, Joyal F, Raynauld JP, Roussin A, Goulet JR, Rich E, Choquette D, Raymond Y, Senecal JL. Updating the American College of Rheumatology preliminary classification criteria for systemic sclerosis: addition of severe nailfold capillaroscopy abnormalities markedly increases the sensitivity for limited scleroderma. Arthritis Rheum 2001, 44:735-736. 10.1002/1529-0131(200103)44:3<735::AID-ANR125>3.0.CO;2-F, 11263791.
16. Hudson M, Taillefer S, Steele R, Dunne J, Johnson SR, Jones N, Mathieu JP, Baron M. Improving the sensitivity of the American College of Rheumatology classification criteria for systemic sclerosis. Clin Exp Rheumatol 2007, 25:754-757.
17. Santiago M, Baron M, Hudson M, Burlingame RW, Fritzler MJ. Antibodies to RNA polymerase III in systemic sclerosis detected by ELISA. J Rheumatol 2007, 34:1528-1534.
18. Mahler M, Raijmakers R, Dahnrich C, Bluthner M, Fritzler MJ. Clinical evaluation of autoantibodies to a novel PM/Scl peptide antigen. Arthritis Res Ther 2005, 7:R704-713. 10.1186/ar1729, 1174964, 15899056.
19. Mahler M, You D, Baron M, Taillefer SS, Hudson M, , Fritzler MJ. Canadian Scleroderma Research Group (CSRG) Anti-centromere antibodies in a large cohort of systemic sclerosis patients: comparison between immunofluorescence, CENP-A and CENP-B ELISA. Clin Chim Acta 2011, 412:1937-1943. 10.1016/j.cca.2011.06.041, 21756890, Canadian Scleroderma Research Group (CSRG).
20. Clements P, Lachenbruch P, Siebold J, White B, Weiner S, Martin R, Weinstein A, Weisman M, Mayes M, Collier D. Inter- and intraobserver variability of total skin thickness score (modified Rodnan TSS) in systemic sclerosis. J Rheumatol 1995, 22:1281-1285.
21. LeRoy EC, Black C, Fleischmajer R, Jablonska S, Krieg T, Medsger TA, Rowell N, Wollheim F. Scleroderma (systemic sclerosis): classification, subsets and pathogenesis. J Rheumatol 1988, 15:202-205.
22. van Gestel A, Haagsma C, van Riel P. Validation of rheumatoid arthritis improvement criteria that include simplified joint counts. Arthritis Rheum 1998, 41:1845-1850. 10.1002/1529-0131(199810)41:10<1845::AID-ART17>3.0.CO;2-K, 9778226.
23. Steele R, Hudson M, Lo E, Baron M, . Canadian Scleroderma Research Group (CSRG) A clinical decision rule to predict the presence of interstitial lung disease in systemic sclerosis. Arthritis Care Res (Hoboken) 2011, Canadian Scleroderma Research Group (CSRG).
24. Hsu VM, Moreyra AE, Wilson AC, Shinnar M, Shindler DM, Wilson JE, Desai A, Seibold JR. Assessment of pulmonary arterial hypertension in patients with systemic sclerosis: comparison of noninvasive tests with results of right-heart catheterization. J Rheumatol 2008, 35:458-465.
25. Medsger TA, Silman AJ, Steen VD, Black CM, Akesson A, Bacon PA, Harris CA, Jablonska S, Jayson MI, Jimenez SA, Krieg T, Leroy EC, Maddison PJ, Russell ML, Schachter RK, Wollheim FA, Zacharaie H. A disease severity scale for systemic sclerosis: development and testing. J Rheumatol 1999, 26:2159-2167.
26. Medsger TA, Bombardieri S, Czirjak L, Scorza R, Della Rossa A, Bencivelli W. Assessment of disease severity and prognosis. Clin Exp Rheumatol 2003, 21:S42-S46.
27. Subcommittee for Scleroderma Criteria of the American Rheumatism Association Diagnostic and Therapeutic Criteria Committee Preliminary criteria for the classification of systemic sclerosis (scleroderma). Arthritis Rheum 1980, 23:581-590. 10.1002/art.1780230510, 7378088, Subcommittee for Scleroderma Criteria of the American Rheumatism Association Diagnostic and Therapeutic Criteria Committee.
28. Peene I, Meheus L, Veys EM, De Keyser F. Diagnostic associations in a large and consecutively identified population positive for anti-SSA and/or anti-SSB: the range of associated diseases differs according to the detailed serotype. Ann Rheum Dis 2002, 61:1090-1094. 10.1136/ard.61.12.1090, 1753972, 12429541.
29. Defendenti C, Atzeni F, Spina MF, Grosso S, Cereda A, Guercilena G, Bollani S, Saibene S, Puttini PS. Clinical and laboratory aspects of Ro/SSA-52 autoantibodies. Autoimmun Rev 2011, 10:150-154. 10.1016/j.autrev.2010.09.005, 20854935.
30. Dugar M, Cox S, Limaye V, Gordon TP, Roberts-Thomson PJ. Diagnostic utility of anti-Ro52 detection in systemic autoimmunity. Postgrad Med J 2010, 86:79-82. 10.1136/pgmj.2009.089656, 20145055.
31. Schulte-Pelkum J, Fritzler M, Mahler M. Latest update on the Ro/SS-A autoantibody system. Autoimmun Rev 2009, 8:632-637. 10.1016/j.autrev.2009.02.010, 19393201.
32. Rutjes SA, Vree Egberts WT, Jongen P, Van Den Hoogen F, Pruijn GJ, Van Venrooij WJ. Anti-Ro52 antibodies frequently co-occur with anti-Jo-1 antibodies in sera from patients with idiopathic inflammatory myopathy. Clin Exp Immunol 1997, 109:32-40. 10.1046/j.1365-2249.1997.4081308.x, 1904727, 9218821.
33. Brouwer R, Hengstman GJ, Vree Egberts W, Ehrfeld H, Bozic B, Ghirardello A, Grondal G, Hietarinta M, Isenberg D, Kalden JR, Lundberg I, Moutsopoulos H, Roux-Lombard P, Vencovsky J, Wikman A, Seelig HP, van Engelen BG, van Venrooij WJ. Autoantibody profiles in the sera of European patients with myositis. Ann Rheum Dis 2001, 60:116-123. 10.1136/ard.60.2.116, 1753477, 11156543.
34. Marie I, Hatron PY, Dominique S, Cherin P, Mouthon L, Menard JF, Levesque H, Jouen F. Short-term and long-term outcome of anti-Jo1-positive patients with anti-Ro52 antibody. Semin Arthritis Rheum
35. Parker JC, Burlingame RW, Bunn CC. Prevalence of antibodies to Ro-52 in a serologically defined population of patients with systemic sclerosis. J Autoimmune Dis 2009, 6:2. 10.1186/1740-2557-6-2, 2654555, 19267890.
36. Ghillani P, Andre C, Toly C, Rouquette AM, Bengoufa D, Nicaise P, Goulvestre C, Gleizes A, Dragon-Durey MA, Alyanakian MA, Chretien P, Chollet-Martin S, Musset L, Weill B, Johanet C. Clinical significance of anti-Ro52 (TRIM21) antibodies non-associated with anti-SSA 60 kDa antibodies: results of a multicentric study. Autoimmun Rev 2011, 10:509-513. 10.1016/j.autrev.2011.03.004, 21447407.
37. Brouwer R, Egberts WV, Hengstman GJD, Rajimakers R, van Engelen BGM, Seelig HP, Renz M, Mierau R, Genth E, Pruijn GJM, Van Venrooij JV. Autoantibodies directed to novel components of the PM/Scl complex, the human exosome. Arthritis Res 2002, 4:134-138. 10.1186/ar389, 83843, 11879549.
38. Anaya JM, Corena R, Castiblanco J, Rojas-Villarraga A, Shoenfeld Y. The kaleidoscope of autoimmunity: multiple autoimmune syndromes and familial autoimmunity. Expert Rev Clin Immunol 2007, 3:623-635. 10.1586/1744666X.3.4.623, 20477166.
39. Hudson M, Rojas-Villarraga A, Coral-Alvarado P, Lopez-Guzman S, Mantilla RD, Chalem P, Baron M, Anaya JM. Polyautoimmunity and familial autoimmunity in systemic sclerosis. J Autoimmun 2008, 31:156-159. 10.1016/j.jaut.2008.05.002, 18644698.
40. Rojas-Villarraga A, Toro CE, Espinosa G, Rodriguez-Velosa Y, Duarte-Rey C, Mantilla RD, Iglesias-Gamarra A, Cervera R, Anaya JM. Factors influencing polyautoimmunity in systemic lupus erythematosus. Autoimmun Rev 2010, 9:229-232. 10.1016/j.autrev.2009.10.001, 19819350.
41. Mackay IR, Leskovsek NV, Rose NR. Cell damage and autoimmunity: a critical appraisal. J Autoimmunity 2008, 30:5-11.
42. Beyer C, Pisetsky DS. The role of microparticles in the pathogenesis of rheumatic diseases. Nature Rev 2010, 6:21-29.
43. Grandinetti KB, Stevens TA, Ha S, Salamone RJ, Walker JR, Zhang J, Agarwalla S, Tenen DG, Peters EC, Reddy VA. Overexpression of TRIB2 in human lung cancers contributes to tumorigenesis through downregulation of C/EBPalpha. Oncogene 2011, 30:3328-3335. 10.1038/onc.2011.57, 21399661.
44. Young JA, Sermwittayawong D, Kim HJ, Nandu S, An N, Erdjument-Bromage H, Tempst P, Coscoy L, Winoto A. Fas-associated death domain (FADD) and the E3 ubiquitin-protein ligase TRIM21 interact to negatively regulate virus-induced interferon production. J Biol Chem 2011, 286:6521-6531. 10.1074/jbc.M110.172288, 3057824, 21183682.
45. Ohmine S, Sakuma R, Sakuma T, Thatava T, Takeuchi H, Ikeda Y. The antiviral spectra of TRIM5alpha orthologues and human TRIM family proteins against lentiviral production. PLoS One 2011, 6:e16121. 10.1371/journal.pone.0016121, 3021539, 21264255.
46. Mallery DL, McEwan WA, Bidgood SR, Towers GJ, Johnson CM, James LC. Antibodies mediate intracellular immunity through tripartite motif-containing 21 (TRIM21). Proc Natl Acad Sci USA 2010, 107:19985-19990. 10.1073/pnas.1014074107, 2993423, 21045130.
47. Yoshimi R, Chang TH, Wang H, Atsumi T, Morse HC, Ozato K. Gene disruption study reveals a nonredundant role for TRIM21/Ro52 in NF-kappaB-dependent cytokine expression in fibroblasts. J Immunol 2009, 182:7527-7538. 10.4049/jimmunol.0804121, 2803686, 19494276.